95% Effective Dose(ED95) of Remimazolam During Dexmedetomidine Pretreatment

NACompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

December 30, 2022

Study Completion Date

January 1, 2023

Conditions
Lung CancerAnesthesia Induction
Interventions
DRUG

Dexmedetomidine

Dexmedetomidine is the most popular adjuvant to anesthesia. Groups was grouped according to different preadministered doses of dexmedetomidine. This allows a more comprehensive assessment of remimazolam under different use. Three groups were set separately, and Group A, Group B, and Group C correspond to 0,0.5, and 1 μg/kg at first 10 mins , respectively.

DRUG

Remimazolam tosilate

Remimazolam tosilate has a short clinical time and a lack of combination with dexmedetomidine for dual-lumen endotracheal intubation. The optimal use dose of Remimazolam tosilate was explored separately from different dexmedetomidine doses.

Trial Locations (1)

200082

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

Shiyou Wei

OTHER